AMGEN INCAMGN
時価総額
$1744.4億
PER
ヒト治療薬の研究・開発・製造・販売の最大手。抗体医薬や希少疾患薬を展開。23年の大型買収、24年の新薬承認、24年に製品売上ボリューム23%増。創業から40年以上、臨床段階を含む多段階パイプライン保有。米国・欧州中心に世界展開。
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| 現金同等物 | 3,287 | 6,946 | 3,257 | 3,805 | 3,731 | 4,144 | 3,241 | 3,800 | 6,945 | 6,037 | 6,266 | 7,989 | 7,629 | 10,944 | 11,973 |
| 有価証券 | 14,135 | 13,695 | 20,804 | 15,596 | 23,295 | 27,238 | 34,844 | 75,756 | 22,359 | 2,874 | 4,381 | 48 | 1,676 | - | - |
| 現金 + 有価証券 | 17,422 | 20,641 | 24,061 | 19,401 | 27,026 | 31,382 | 38,085 | 79,556 | 29,304 | 8,911 | 10,647 | 8,037 | 9,305 | 10,944 | 11,973 |
| 売掛金 | 2,335 | 2,896 | 2,518 | 2,697 | 2,546 | 2,995 | 3,165 | 3,237 | 3,580 | 4,057 | 4,525 | 4,895 | 5,563 | 7,268 | 6,782 |
| 商品及び製品 | 2,022 | 2,484 | 2,744 | 3,019 | 2,647 | 2,435 | 2,745 | 2,834 | 2,940 | 3,584 | 3,893 | 4,086 | 4,930 | 9,518 | 6,998 |
| 流動資産合計 | 23,129 | 27,593 | 31,209 | 27,367 | 34,713 | 38,518 | 46,010 | 49,476 | 37,618 | 18,440 | 21,144 | 19,385 | 22,186 | 30,332 | 29,030 |
| 有形固定資産 | 5,522 | 5,420 | 5,326 | 5,349 | 5,223 | 4,907 | 4,961 | 4,989 | 4,958 | 4,928 | 4,889 | 5,184 | 5,427 | 5,941 | 6,543 |
| 固定資産合計 | 20,357 | 21,278 | 23,089 | 38,758 | 34,296 | 33,058 | 31,616 | 30,478 | 28,798 | 41,267 | 41,804 | 41,780 | 42,935 | 66,822 | 62,809 |
| 総資産 | 43,486 | 48,871 | 54,298 | 66,125 | 69,009 | 71,576 | 77,626 | 79,954 | 66,416 | 59,707 | 62,948 | 61,165 | 65,121 | 97,154 | 91,839 |
| 買掛金 | 716 | 642 | 905 | 787 | 1,212 | 965 | 917 | 1,352 | 1,207 | 1,371 | 1,421 | 1,366 | 1,572 | 1,590 | 1,908 |
| 一年内返済予定の長期借入金 | - | - | - | - | 500 | 2,250 | 4,403 | 1,152 | 4,419 | 2,953 | 91 | 87 | 1,591 | 1,443 | 3,550 |
| 流動負債合計 | 6,570 | 5,754 | 8,191 | 7,947 | 7,008 | 8,667 | 11,204 | 9,020 | 13,488 | 12,835 | 11,653 | 12,184 | 15,687 | 18,392 | 23,099 |
| 長期借入金 | - | - | - | - | 30,215 | 29,306 | 30,193 | 34,190 | 29,510 | 26,950 | 32,895 | 33,222 | 37,354 | 63,170 | 56,549 |
| 資本金及び資本剰余金 | 27,299 | 27,777 | 58,674 | 29,891 | 30,410 | 30,649 | 30,784 | 30,992 | 31,246 | 31,531 | 31,802 | 32,096 | 32,514 | 33,070 | 33,533 |
| 利益剰余金 | -3,508 | -8,919 | -10,423 | -7,634 | -4,624 | -2,086 | -438 | -5,072 | -17,977 | -21,330 | -21,408 | -24,600 | -28,622 | -26,549 | -27,590 |
| 株主資本 | 23,944 | 19,029 | 19,060 | 22,096 | 25,778 | 28,083 | 29,875 | 25,241 | 12,500 | 9,673 | 9,409 | 6,700 | 3,661 | 6,232 | 5,877 |
| 有利子負債合計 | - | - | - | - | 30,715 | 31,429 | 34,596 | 35,342 | 33,929 | 29,903 | 32,986 | 33,309 | 38,945 | 64,613 | 60,099 |
| 純有利子負債 | - | - | - | - | 3,689 | 47 | -3,489 | -44,214 | 4,625 | 20,992 | 22,339 | 25,272 | 29,640 | 53,669 | 48,126 |
| DEレシオ（％） | - | - | - | - | 119.2 | 111.9 | 115.8 | 140 | 271.4 | 309.1 | 350.6 | 497.1 | 1,063.8 | 1,036.8 | 1,022.6 |
| 運転資本 |